Items where Author is "Terheyden, P."

Article

Klespe, K. C. and Kochanek, C. and Schadendorf, D. and Ugurel, S. and Mohr, P. and Meier, F. and Weichenthal, M. and Pfoehler, C. and Haferkamp, S. and Herbst, R. and Terheyden, P. and Meiss, F. and Ulrich, J. and Utikal, J. S. and Leiter-Stoeppke, U. and Gutzmer, R. and von Wasielewski, I. (2023) Influence of BRAF mutation status on the effectiveness of immune checkpoint inhibition in metastatic melanoma - a multicenter study from the ADOREG. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 21. pp. 28-29. ISSN 1610-0379, 1610-0387

Kochanek, C. and Livingstone, E. and Ugurel, S. and Meier, F. and Mohr, P. and Terheyden, P. and Haferkamp, S. and Kaatz, M. and Sachse, M. M. and Meiss, F. and Pfoehler, C. and Leiter-Stoeppke, U. and Ulrich, J. and Schadendorf, D. and Weichenthal, M. and Angela, Y. and Schaper-Gerhardt, K. and Gutzmer, R. (2023) Influence of osteoprotective therapy on the effectiveness of immune checkpoint inhibition in melanoma - an evaluation of the ADOReg. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 21. pp. 49-50. ISSN 1610-0379, 1610-0387

Gutzmer, R. and Ugurel, S. and Eigentler, T. and Mohr, P. and Weichenthal, M. and Gebhardt, C. and Goeppner, D. and Haferkamp, S. and Herbst, R. and Kaehler, K. C. and Kreuter, A. and Meier, F. and Pfoehler, C. and Sachse, M. M. and Herber, M. and Terheyden, P. and Ulrich, J. and Utikal, J. S. and von Wasielewski, I. and Schadendorf, D. (2023) Relationship between baseline health-related quality of life (HRQoL) measures and clinical outcomes of nivolumab (NIVO) or nivolumab plus ipilimumab (NIVO plus IPI) in patients (pts) with unresectable or metastatic melanoma using real-world data from the non-interventional study (NIS) NICO in Germany. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 21. pp. 6-8. ISSN 1610-0379, 1610-0387

Garbe, Claus and Terheyden, P. and Keilholz, U. and Koelbl, O. and Hauschild, A. (2008) Treatment of Melanoma. DEUTSCHES ARZTEBLATT INTERNATIONAL, 105 (49). pp. 845-851. ISSN 1866-0452

Conference or Workshop Item

Wagner, N. and Lenders, M. M. and Kühl, K. and Reinhardt, L. and Fuchss, M. and Ring, N. and Richtig, G. and Ebel, C. and Andre, F. and Stäger, R. and Zellweger, C. and Stürmer, S. H. and Lang, R. and Paar, M. and Gussek, P. and Kimeswenger, S. and Oellinger, A. and Amaral, T. and Forschner, A. and Leiter-Stöppke, U. and Weide, B. and Gassenmaier, M. and Schraag, A. and Klumpp, B. and Hoetzenecker, W. and Ziemer, M. and Berking, C. and Mangana, J. and Nguyen, V. A. and Terheyden, P. and Richtig, E. and Loquai, C. and Diem, S. and Cozzio, A. and Röcken, M. and Garbe, C. and Gebhardt, C. and Meier, F. and Eigentler, T. and Flatz, L. (2022) FV04 Site-specific tumor response and survival in patients with metastatic melanoma receiving immune checkpoint inhibition or targeted therapy: implications for treatment choice. In: 32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover.

Franklin, C. and Mohr, P. and Meier, F. and Weichenthal, M. and Grimmel-Mann, I. and Gutzmer, R. and Utikal, J. S. and Terheyden, P. and Herbst, R. and Haferkamp, Sebastian and Pföhler, C. and Leiter-Stöppke, U. and Ziller, F. and Meiß, F. and Ulrich, J. and Kreuter, A. and Gebhardt, C. and Welzel, J. and Schilling, B. and Kaatz, M. and Scharfetter-Kochanek, K. and Dippel, E. and Nashan, D. and Sachse, M. M. and Weishaupt, C. and Löffler, H. and Gambichler, T. and Loquai, C. and Heinzerling, L. and Grabbe, S. and Debus, D. and Schley, G. and Weyandt, G. and Trommer, M. and Lodde, G. and Placke, J. M. and Zimmer, L. and Livingstone, E. and Horn, S. and Schadendorf, D. and Ugurel, S. (2022) FV20 Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. In: 32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover.

Kreft, S. and Glutsch, V. and Zaremba, A. and Schummer, P. and Mohr, P. and Grimmelmann, I. and Gutzmer, R. and Meier, F. and Pföhler, C. and Sachse, M. M. and Meiß, F. and Forschner, A. and Haferkamp, Sebastian and Welzel, J. and Terheyden, P. and Herbst, R. and Utikal, J. S. and Kaatz, M. and Weishaupt, C. and Kreuter, A. and Debus, D. and Dücker, P. and Sindrilaru, A. and Löffler, H. and Schley, G. and Weichenthal, M. and Schadendorf, D. and Ugurel, S. and Gesierich, A. and Schilling, B. (2022) eP001 MAPKinase Inhibition nach Versagen einer PD-1 basierten Immuncheckpoint Blockade in Patienten:innen mit fortgeschrittenem Melanom – eine Auswertung des multizentrischen prospektiven Hautkrebsregisters ADOREG. In: 32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover.

Franklin, C. and Mohr, P. and Bluhm, L. and Grimmelmann, I. and Gutzmer, R. and Meier, F. and Garzarolli, M. and Weichenthal, M. and Herbst, R. and Pföhler, C. and Terheyden, P. and Utikal, J. S. and Ulrich, J. and Debus, D. and Haferkamp, Sebastian and Kaatz, M. and Forschner, A. and Leiter-Stöppke, U. and Nashan, D. and Kreuter, A. and Sachse, M. M. and Welzel, J. and Heinzerling, L. and Meiß, F. and Weishaupt, C. and Gambichler, T. and Weyandt, G. and Dippel, E. and Schatton, K. and Celik, E. and Trommer, M. and Helfrich, I. and Rösch, A. and Zimmer, L. and Livingstone, E. and Schaden-Dorf, D. and Horn, S. and Ugurel, S. (2022) eP003 Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. In: 32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover.

Schumann, K. and Mangana, J. and Dummer, R. and Sindrilaru, M. and Reinhardt, L. and Meier, F. and Gutzmer, R. and Schatton, K. and Amaral, T. and Eigentler, T. and Peitsch, W. and Hillen, U. and Ziller, F. and Debus, D. and Maul, L. and Weishaupt, C. and Börger, S. and Haferkamp, S. and Terheyden, P. and Thiem, A. and Sachse, M. and Öllinger, A. and Hötzenecker, W. and Heppt, M. and Hansel, G. and Posch, C. (2021) Adjuvant melanoma treatment: real-world data from the DACH region. In: 47th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF), March 04‐06, 2021, Virtual.

Schadendorf, D. and Ugurel, S. and Eigentler, T. and Mohr, P. and Weichenthal, M. and Gebhardt, C. and Göppner, D. and Haferkamp, Sebastian and Herbst, R. and Kähler, K. and Kreuter, A. and Meier, F. and Pföhler, C. and Sachse, M. M. and Sickmann, T. and Terheyden, P. and Ulrich, J. and Utikal, J. S. and Grimmelmann, I. and Gutzmer, R. (2021) Age-dependent Efficacy and Safety of Nivolumab (NIVO) as Monotherapy or Combination Therapy with Ipilimumab (NIVO plus IPI) in Patients with advanced Melanoma in the non-interventional Study (NIS) NICO. In: 31. Deutscher Hautkrebskongress (ADO-Jahrestagung), 8.–11. September 2021, hybrid.

Gutzmer, R. and Eigentler, T. and Mohr, P. and Weichenthal, M. and Dücker, P. and Gebhardt, C. and Göppner, D. and Grimmelmann, I. and Haferkamp, S. and Kähler, K. C. and Meier, F. and Pföhler, C. and Sickmann, T. and Sindrilaru, A. and Terheyden, P. and Ugurel, S. and Ulrich, J. and Utikal, J. and Weishaupt, C. and Schadendorf, D. (2021) Comparison of effectiveness and safety of nivolumab monotherapy or in combination therapy with ipilimumab in therapy-naive and pretreated patients with advanced melanoma within the German noninterventional study NICO. In: Congress of the European Society for Medical Oncology (ESMO), SEP 16 - 21, 2021, Virtuell.

Weichenthal, M. and Mohr, P. and Leiter-Stoeppke, U. and Ugurel, S. and Kaehler, K. and Gutzmer, R. and Pfoehler, C. and Hassel, J. C. and Nashan, D. and Terheyden, P. and Schell, B. and Utikal, J. S. and Kreuter, A. and Haferkamp, S. and Kaune, K. and Berking, C. and Debus, D. and Ulrich, J. and Dabrowski, E. and Eigentler, T. and Welzel, J. and Herbst, R. and Loquai, C. and Meier, F. and Schadendorf, D. (2021) The Effects of Brain Metastases in Melanoma Patients on anti-PD1 Antibody Therapy with Pembrolizumab. In: 31. Deutscher Hautkrebskongress (ADO-Jahrestagung), 8.–11. September 2021, hybrid.

Thiem, A. and Mashhadiakbar, P. and Hassel, J. C. and Grimmelmann, I. and Gutzmer, R. and Schlaak, M. and Heppt, M. and Dücker, P. and Hüning, S. and Schulmeyer, L. and Schilling, B. and Haferkamp, S. and Ziemer, M. and Moritz, R. K. C. and Hagelstein, V. and Terheyden, P. and Posch, C. and Gaiser, M. R. and Müller, B. and Kropp, P. and Tietze, J. K. and Emmert, S. (2021) Patient-oriented Comparison of Systemic Therapies for Patients with advanced Melanoma - A multicenter Cross-sectional Study. In: 31. Deutscher Hautkrebskongress (ADO-Jahrestagung), 8.–11. September 2021, hybrid.

Thiem, A. and Mashhadiakbar, P. and Cussigh, Ch. and Hassel, J. C. and Grimmelmann, I. and Gutzmer, R. and Schlaak, M. and Heppt, M. V. and Dücker, P. and Hüning, S. and Schulmeyer, L. and Schilling, B. and Haferkamp, S. and Ziemer, M. and Moritz, R. K. C. and Hagelstein, V. and Terheyden, P. and Posch, Ch. and Gaiser, M. R. and Müller, B. and Kropp, P. and Emmert, St. and Tietze, J. K. (2021) Patient-oriented Comparison of Systems Therapies for advanced Melanoma: a multicenter Cross-Sectional Study. In: 92. Jahrestagung der Norddeutschen Dermatologischen Gesellschaft, 27. - 29. August 2021, Rostock / Warnemünde / Mecklenburg-Vorpommern.

Haist, M. and Stege, H. and Mohr, P. and Meier, F. and Schadendorf, D. and Ugurel, S. and Livingstone, E. and Zimmer, L. and Herbst, R. and Pföhler, C. and Kähler, K. and Weichenthal, M. and Terheyden, P. and Nashan, D. and Debus, D. and Kaatz, M. and Ziller, F. and Haferkamp, S. and Forschner, A. and Leiter-Stöppke, U. and Kreuter, A. and Ulrich, J. and Kleemann, J. and Grabbe, S. and Loquai, C. (2021) Termination of targeted Therapy with BRAF-/MEK Inhibitors after an initial complete Response in Patients with metastatic Melanoma and its clinical Implications - a retrospective, multicenter ADOReg Study. In: 31. Deutscher Hautkrebskongress (ADO-Jahrestagung), 8.–11. September 2021, hybrid.

Spassova, I. and Ugurel, S. and Zimmer, L. and Schadendorf, D. and Terheyden, P. and Andtback, H. B. and Villabona, L. and Leiter-Stoeppke, U. and Eigentler, T. and Loquai, C. and Hassel, J. C. and Gambichler, T. and Haferkamp, S. and Mohr, P. and Pfoehler, C. and Heinzerling, L. and Horny, K. and Habermann, D. and Hoffmann, D. and Becker, J. C. (2020) Immune-Checkpoint-Blockade for Merkel Cell Carcinoma: Clinical and molecular Biomarker-Analysis. In: 30. Deutscher Hautkrebskongress (ADO‐Jahrestagung), 9. bis 12. September 2020, Virtuell.

Gilde, C. and Ugurel, S. and Mohr, P. and Weichenthal, M. and Terheyden, P. and Meier, F. and Pfoehler, C. and Leiter-Stoeppke, U. and Kaatz, M. and Haferkamp, S. and Ulrich, J. and Kochanek, C. and Schadendorf, D. and Gutzmer, R. (2020) Influence of the BRAF-V600 Mutation Status on the Efficiency of an Immune Checkpoint Blockade - an Evaluation of the ADOREG. In: 30. Deutscher Hautkrebskongress (ADO‐Jahrestagung), 9. bis 12. September 2020, Virtuell.

Gutzmer, R. and Eigentler, T. and Mohr, P. and Weichenthal, M. and Duecker, P. and Gebhardt, C. and Goeppner, D. and Haferkamp, S. and Kaehler, K. and Meier, F. and Pfoehler, C. and Satzger, I. and Sickmann, T. and Sindrilaru, A. and Terheyden, P. and Ugurel, S. and Ulrich, J. and Utikal, J. and Weishaupt, C. and Schadendorf, D. (2020) Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO plus IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO. In: ESMO Virtual Congress, SEP 19-OCT 18, 2020, ELECTR NETWORK.

Other

Leiter-Stoeppke, U. and Loquai, C. and Meier, F. and Rafei-Shamsabadi, D. and Hassel, J. and Glutsch, V. and Sirokay, J. and Schlecht, N. and Ruebben, A. and Gutzmer, R. and Kaehler, K. and Gambichler, T. and Schatton, K. and Pfoehler, C. and Franklin, C. and Terheyden, P. and Haferkamp, S. and Mohr, P. and Heinzerling, L. and Meiwes, A. and Keim, U. and Becker, J. C. and Bischof, L. and Livingstone, E. and Schadendorf, D. and Ugurel, S. (2019) Limited Effect of Anti-PD-1 in advanced Skin Tumors of Patients with hemato-oncological Primary Disease: A retrospective multi-center Study of ADO. WILEY, HOBOKEN.

Weichenthal, M. and Gutzmer, R. and Eigentler, T. and Mohr, P. and Goeppner, D. and Haferkamp, S. and Herber, M. and Herbst, R. and Meier, F. and Meiss, F. and Pfoehler, C. and Schneider, S. W. and Terheyden, P. and Ulrich, J. and Utikal, J. and Weishaupt, C. and Welzel, J. and Schadendorf, D. (2019) Real-world Data on advanced Melanoma: First Data from a national, prospective, non-interventional Study of Nivolumab in Combination with Ipilimumab or as Nivolumab Monotherapy (NICO). WILEY, HOBOKEN.

Haferkamp, S. and Alter, M. and Debus, D. and Schilling, B. and Pinter, A. and Terheyden, P. and Utikal, J. and Sachse, M. M. and Haalck, T. and Wolf, I. (2019) Therapeutic Reality of Patients with BRAF-mutated advanced/metastatic Melanoma in Germany and Austria. WILEY, HOBOKEN.

Gutzmer, R. and Eigentler, T. and Mohr, P. and Becker, S. and Haferkamp, S. and Meiss, F. and Pfoehler, C. and Satzger, I. and Schneider, S. W. and Terheyden, P. and Ulrich, J. and Utikal, J. and Weichenthal, M. and Weishaupt, C. and Zimmer, L. and Schadendorf, D. (2018) NICO - a national prospective non-interventional Study (NIS) with Nivolumab as Monotherapy or in combination with Ipilimumab in Patients with advanced (inoperable or metastatic) Melanoma to collect real-world data. WILEY, HOBOKEN.

Heppt, M. and Heinzerling, L. and Kaehler, K. and Forschner, A. and Kirchberger, M. and Loquai, C. and Meissner, M. and Meier, F. and Terheyden, P. and Schell, B. and Herbst, R. and Goeppner, D. and Kiecker, F. and Rafei-Shamsabadi, D. and Haferkamp, S. and Huber, M. and Utikal, J. and Ziemer, M. and Bumeder, I and Pfeiffer, C. and Schd-Trcka, S. and Schmid-Tannwald, C. and Tietze, J. and Eigentler, T. and Berking, C. (2017) Prognostic factors and outcomes in metastatic uveal melanoma treated with PD-1 or combined PD-1 / CTLA-4 inhibition. WILEY, HOBOKEN.